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Mutations in two genes encoding cell cycle regulatory proteins have been shown to cause familial cutaneous malignant melanoma
(CMM). About 20% of melanoma-prone families bear a point mutation in the CDKN2A locus at 9p21, which encodes two unrelated
proteins, p16
INK4a and p14
ARF. Rare mutations in CDK4 have also been linked to the disease. Although the CDKN2A gene has been
shown to be the major melanoma predisposing gene, there remains a significant proportion of melanoma kindreds linked to 9p21 in
which germline mutations of CDKN2A have not been identified through direct exon sequencing. The purpose of this study was to
assess the contribution of large rearrangements in CDKN2A to the disease in melanoma-prone families using multiplex ligation-
dependent probe amplification. We examined 214 patients from independent pedigrees with at least two CMM cases. All had been
tested for CDKN2A and CDK4 point mutation, and 47 were found positive. Among the remaining 167 negative patients, one carried a
novel genomic deletion of CDKN2A exon 2. Overall, genomic deletions represented 2.1% of total mutations in this series (1 of 48),
confirming that they explain a very small proportion of CMM susceptibility. In addition, we excluded a new gene on 9p21, KLHL9,a s
being a major CMM gene.
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The incidence of cutaneous malignant melanoma (CMM) (MIM
no. 600160) has been increasing rapidly in the Caucasian
population in recent decades. Melanoma is a complex and
heterogeneous disease with genetic and environmental factors
contributing to its development. Population-based studies in Utah
and Sweden have reported approximately 2- and 3-fold increased
risk of melanoma, respectively, in first-degree relatives of
melanoma probands (Goldgar et al, 1994; Hemminki et al, 2003).
Indeed, about 10% of CMM cases occur in a familial setting.
Familial melanoma is usually defined as a cluster of two or more
first-degree relatives with melanoma. Two high-risk genes have
been identified: the cell cycle regulator CDKN2A on chromosomal
band 9p21 (Hussussian et al, 1994) and the cyclin-dependent
kinase-4 (CDK4) on chromosomal band 12p14 (Zuo et al, 1996),
the products of which are known to be components of potent
tumour-suppression pathway. The CDKN2A gene is the major
high-risk CMM susceptibility gene identified to date, as germline
mutations in this gene have been found in about 20–40% of
melanoma-prone families worldwide (Hayward, 2003). It encodes
two distinct proteins, translated in alternate reading frames, from
alternatively spliced transcripts. The a transcript encodes the p16
inhibitor of cyclin-dependent kinase type 4 protein (p16
INK4a); the
smaller b transcript specifies the alternative product p14
ARF. Both
of these proteins are involved in cell cycle regulation. Only two
germline mutations in CDK4 (MIM no. 123829) have been reported
worldwide in a total of six CDKN2A mutation-negative familial
melanoma kindreds, and all mutations occur at the arginine
encoded by codon 24 in exon 2 of the gene. This arginine directly
interacts with p16, and mutations affecting this codon have the
same functional effect as a p16 mutation (Zuo et al, 1996; Soufir
et al, 1998; Molven et al, 2005).
Although approximately 50% of melanoma-prone families
display linkage to 9p21, only about half of these have been
identified as carriers of a mutation in the CDKN2A gene
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s(Hussussian et al, 1994; Kamb et al, 1994; Harland et al, 1997; Borg
et al, 2000; Laud et al, 2006). These studies suggest, besides the
involvement of CDKN2A in susceptibility to melanoma, the
possibility of the existence of additional tumour suppressor loci
on chromosome 9p21. At the somatic level, the very low frequency
of disease-causing alterations (by mutation or inactivation by loss
of expression) of the CDKN2A gene in sporadic CMM cases with
allelic losses of 9p21 is again consistent with the presence of
additional tumour suppressor gene(s) within this chromosomal
area (Gonzalgo et al, 1997; Ruiz et al, 1998; Wagner et al, 1998).
CDKN2B, located about 30kb centromeric from CDKN2A and
coding the cyclin-dependent kinase inhibitor p15
INK4b, was the
first obvious candidate gene but has been excluded as being a high
penetrance susceptibility gene for CMM (Platz et al, 1997; Laud
et al, 2006). The question of whether or not large genomic
deletions, undetectable by traditional PCR-amplification and
sequencing of individual exons, may be the cause of such
unexplained familial clustering of melanoma has been raised,
and few authors have searched for large CDKN2A/ARF deletions or
rearrangements (Fitzgerald et al, 1996; Bahuau et al, 1998;
Randerson-Moor et al, 2001; Debniak et al, 2004; Mistry et al,
2005; Knappskog et al, 2006, Erlandson et al, 2007). To date,
germline large deletions have been characterised at the 9p21 locus
in only six families worldwide. A deletion involving CDKN2A
exon1a, 2, and 3 and a deletion removing exon 1a and half of exon
2 were described in two melanoma-prone kindreds, originated
from UK and from Norway, respectively (Mistry et al, 2005;
Knappskog et al, 2006). Large deletions have also been found in
families with combined proneness to melanoma and nervous
system tumours (NST): a gross deletion ablating the whole
CDKN2A and CDKN2B genes has been reported in a French
family (Bahuau et al, 1998; Pasmant et al, 2007), and a deletion of
p14
ARF-specific exon 1b of the CDKN2A gene has been found in
one US family and in two UK families (Bahuau et al, 1998;
Randerson-Moor et al, 2001; Mistry et al, 2005; Laud et al, 2006). A
large duplication of the CDKN2A/CDKN2B loci has also been
reported in a melanoma patient from a Swedish family, but the
clinical significance of this variant is not evident (Erlandson et al,
2007).
The purpose of the present study was to estimate the prevalence
of large deletions at the 9p21 locus, which participated in CMM
families originating from France, using the multiplex ligation-
dependent probe amplification (MLPA) analysis (Schouten et al,
2002). This quantitative technique was used because it enabled
fine-scale mapping at the CDKN2A locus and allowed other
flanking genes to be screened (24 sites of interest on 9p in total).
This approach led us to characterise a novel deletion of CDKN2A
exon 2 (affecting both p14
ARF and p16
INK4a) in one patient.
Moreover, it led to the identification of a new variant within the
gene KLHL9 (Kelch-like 9) located approximately 630kb from
CDKN2A in another patient. Because this variant was not found in
a control population, this finding prompted us to investigate this
candidate in high-risk melanoma families with no mutation of
CDKN2A.
PATIENTS, MATERIALS AND METHODS
Study participants
The patients in this study were enroled through the Department of
Dermatology at the Institut de Cance ´rologie Gustave Roussy and
the other French Hospitals that constitute the Familial Melanoma
Study Group, as part of the French Familial Melanoma Project
(Grange et al, 1995). A total of 214 index cases from independent
pedigrees with at least two melanoma cases were identified
between 1986 and 2005. These cases had confirmed diagnosis of
CMM, through medical records, review of pathological material,
and/or pathological reports. Among the 214 index cases, direct
sequencing of CDKN2A (exon 1b,1 a, 2 and 3) or CDK4 (exon 2)
had identified CDKN2A point mutations or small insertions/
deletions in 46 families, and the CDK4 codon 24 point mutation in
one family (Supplementary Table 1). The remaining 167 index
cases were included in the present study to evaluate the
contribution of large genomic deletions at 9p21 in the French
series. Probands from these negative families displayed the
following inclusion criteria: a) families with at least three affected
members (‘high-risk family set’, N¼42), (b) families with two
first-degree relatives affected with confirmed melanoma (N¼102),
(c) families with two second degree relatives affected with
confirmed melanoma (N¼23). The mutation scanning of KLHL9
was performed in patients from the high-risk family set, including
the 42 index cases and 48 additional affected members. Our control
population consisted of 188 DNA samples prepared from
lymphocytes of blood donors born in France. The study was
approved by an institutional review board-approved protocol
(CCPPRB no: 01-09-05, Paris Necker). It was conducted according
to the Declaration of Helsinki Principles. All participating subjects
signed informed consent before providing blood samples. DNA
from participants was extracted from peripheral blood lympho-
cytes, using the QIAamp DNA Blood mini kit (QIAGEN, Hilden,
Germany), according to the manufacturer’s guidelines.
Large insertion and deletion analysis
Deletion screening of the CDKN2A locus was carried out using the
9p21 Multiplex ligation-dependent probe amplification kit (P024),
according to the supplied protocol (MRC-Holland, Amsterdam,
the Netherlands) (Schouten et al, 2002; Mistry et al, 2005). The
technique and preparation of the probes used in this kit are
described elsewhere (Schouten et al, 2002; Mistry et al, 2005). Gene
dosage quotients for 9 CDKN2A locus sites and for 15 other 9p
genes sites were determined to screen for deletions at 9p. In total,
21 specific probes mapped to 9p21 (three within CDKN2B, three
within MTAP, one within IFNA1, one within KIAA1354 (KLHL9),
one within IFNW1, one within IFNB1, one within ELAVL2, one
within TEK), two probes mapped to 9p22 (both within MLLT3)
and one probe mapped to 9p24 (within FLJ00026 (DOCK8)).
Calculation of dosage quotients was carried out as described by
Mistry et al (2005). Theoretically, gene dosage quotients close to
1.0 indicate two copies present (that is, wild-type); 0.5, one copy
absent (that is, hemizygous); 0.0, both copies absent (that is,
homozygous deletion); and 1.5, one copy duplicated. Quotients
were scored according to observations made from known samples:
wild type if the quotient was between 0.8 and 1.2, hemizygous
deletion if the quotient was between 0.4 and 0.7, homozygous
deletion if the quotient was between 0.0 and 0.2. All other values
were considered undetermined.
RT–PCR analysis of CDKN2A transcripts
RNA from patient carrying the heterozygous CDKN2A deletion was
extracted from peripheral blood lymphocytes using the AllPrep
DNA/RNA Mini Kit (QIAGEN), and cDNA was synthesized by
reverse transcription using the Superscript reverse transcriptase
system (Invitrogen, Paisley, UK) according to the manufacturer’s
recommendations.
Characterisation of CDKN2A deletion breakpoint
Long-range PCRs were performed with the Expandt Long
Template PCR System (Boehringer Mannheim, Mannheim,
Germany) as recommended by the manufacturer. Primers were
designed to amplify the region encompassing the putative deletion
between exon 1a and exon 3. Forward primer and reverse primer
amplified a 355bp mutant p16
INK4-encoding cDNA fragment
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slacking exon 2, the wild type cDNA fragment being 662bp long
(Table 1). To characterise the intronic deletion breakpoints,
forward primer in exon 1a and reverse primer in intron 2
amplified a 3705bp genomic fragment for the wild type allele and a
770bp fragment for the mutant allele (Table 1).
PCR products were sequenced with the Big Dye Terminator,
version 3.0 (Applied Biosystems, Foster City, CA, USA) on the ABI
Prism
r 3730 Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA).
Direct sequencing of KLHL9
Primers used for the sequencing of KLHL9 are given in Table 1.
The amplification protocol consisted of 35 cycles with temperature
steps at 94, 60, and 721C for 30s each.
RESULTS
Contribution of genomic rearrangements at 9p21
Among the 167 index cases screened for genomic rearrangements
at 9p21, 166 patients present a gene dosage quotient close to one
(between 0.8 and 1.2), indicating no alteration in gene copy
numbers, and one patient (0.6%) was identified to carry a
hemizygous deletion of CDKN2A exon 2, as gene dosage quotient
was close to 0.5. Multiplex ligation-dependent probe amplification
probes at exon 1b, exon1a and exon 3 of CDKN2A did not reveal a
reduced gene dosage quotient for this patient, indicating that,
according to position of probes within the exons, the deletion was
at most 6.4kb long with intronic breakpoints, extending at most
from the first base of intron 1a to the last base of intron 2
(Figure 1A). These results were confirmed by quantitative multi-
plex PCR of short fluorescent fragments with primers specifically
amplifying CDKN2A exon 1b, exon1a, exon 2 and exon 3 (data not
shown) (Casilli et al, 2002). To verify whether or not the putative
CDKN2A mutation generated aberrant mRNAs, long range PCR
was performed on the patient cDNA. Sequencing of the PCR
product confirmed that the germline deletion leads to an aberrant
p16
INK4a transcript, lacking the 307bp corresponding to CDKN2A
exon 2 (Figure 1). To determine the exact nature of the CDKN2A
gene aberration, long range PCR and sequencing was performed
on the patient’s genomic DNA. This revealed a 2935bp deletion
extending from nucleotide position þ1712bp from end of exon 1a
to position þ873bp from end of exon 2 (Figure 1). It is worth
noting that the deletion breakpoints did not lie within ALU
sequences, and that such repetitive elements could not explain the
occurrence of a rearrangement at this genomic position.
The patient carrying this novel deletion of CDKN2A presented
with dysplastic nevus syndrome and developed five primary
melanomas between 45 and 51 years of age. He was the index case
of a melanoma-prone family of three affected members: his father
had a confirmed diagnosis of melanoma at the age of 50, and his
sister was also reported to have had melanoma, but no pathological
report was available for her (Figure 2). We were unable to
investigate the co-segregation of the genomic deletion with
melanoma in this pedigree because of unavailability of biological
material for the index case’s relatives. In addition, the patient’s
uncle died of pancreatic cancer, a cancer that had been associated
with CDKN2A germline mutations (Goldstein et al, 1995; Goldstein
et al, 2006), and three other family members died of cancer, but no
clinical details were reported to the clinician (Figure 2).
KLHL9 on 9p21 as a new candidate gene for susceptibility
to melanoma
For a second patient diagnosed with melanoma at the age of 54,
and belonging to a different melanoma -prone pedigree, a dosage
quotient close to 0.5 was obtained for a 9p probe specific of the 50
end of the transcription unit of the single exon gene KLHL9
(Kelch-like 9, previously named KIAA1354), suggesting a hemi-
zygous deletion in this gene located about 630kb telomeric from
CDKN2A (Figure 3). Subsequent direct sequencing of the entire
exon led to the identification of a heterozygous nucleotidic
variation (A4G) located 16bp upstream of the START codon of
KLHL9 (NM_018847), that prevents the ligation reaction of the two
contiguous probes used for MLPA, for the G allele (Figure 4).
Although the various in silico tools (PupaSuite, http://pupasuite.
bioinfo.cipf.es/, CorePromoter,http://rulai.cshl.org/tools/genefinder/
CPROMOTER/, TFSEARCH, http://www.cbrc.jp/research/db/
TFSEARCH.html, TESS, http://www.cbil.upenn.edu/cgi-bin/tess/
tess) did not suggest that the presence of the G allele would have
direct functional effects on the activity of the promoter, this new
variant was not described in the public SNPs databases
(ENSEMBL, http://www.ensembl.org/, dbSNP, http://www.ncbi.
nlm.nih.gov/SNP, and HAPMAP, http://www.hapmap.org/) and
was absent in 188 unrelated controls from France (376 chromo-
somes). DNA was available for the two unaffected siblings of the
patient, and MLPA and sequence analysis revealed that one of the
patient’s sisters, unaffected at age 62, also carried the –16 A4G
allele. The father of the patient died of melanoma metastases to the
brain at the age of 70, and his paternal grandmother had a
suspicious pigmented lesion on her face and died of thyroid cancer
at the age of 80. Unfortunately, material was not available for any
of them, and co-segregation of the variant with skin lesion could
not be investigated (Figure 5).
Beside its genomic location at 9p21, KLHL9 appeared to
represent a good candidate for melanoma susceptibility as it has
been reported that loss of function of BTB/kelch repeat proteins
may contribute to tumorigenesis (Adams et al, 2000; Liang et al,
2004; Yoshida, 2005). Therefore, we undertook the resequencing of
the 4.3kb unique exon of the gene in 90 CMM patients belonging
to the high-risk family set (that is, families counting at least 3
Table 1 Primer sequences for characterization of CDKN2A exon 2 deletion and screening of the KLHL9 gene
Gene Amplicon Forward sequence 50 430 Reverse sequences 50430
CDKN2A Exon 1a–Exon 3 CGCCAGCACCGGAGGAAGAA CCTGTAGGACCTTCGGTGACTGA
Exon 1a–Intron 2 TTTTCTTTTTGCTTTGGATTTCTA AAGGGAGGAGGGAAGAAATGA
KLHL9 Amplicon 1 GCTGACTGACGAGGTCTGG GAGATGCAAGCCGGATAAAG
Amplicon 2 TGGTCCTGCTACAGGGTGAT GCAATTCGTCCAACCTCAAC
Amplicon 3 TGGACAATCTTCAGGACACACT CTGCTGCCTCAAAACTCCTC
Amplicon 4 ACCTGCGTGAATTTGCTTTT CATGGGTAATTCCTCCTGAAA
Amplicon 5 CTGGTGAACTGGCCACAGTA GTGACCCAGGGTTTTCTTCA
Amplicon 6 GACCCAGAAAAAGATGAGTGG AATGCAACCACACAATCGAG
Amplicon 7 GTTGAGTTTTCATCTTTGACTCCA TGCACAAAAGCAGTTCTCTGA
Amplicon 8 AAATCGACAACCAAATTTGTCA TGTGGTTCTCAACCAATAGGG
Amplicon 9 ATTCCCAAAGAAGCCAGCTA GGATGCACTTCTTGCTTATTCA
Amplicon 10 GCATTGGCAGAAATTTTCATACT CACCTTGATATGTCAGAATAAGCAC
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in the promoter of KLHL9 was not found in this series, and no
other mutation elsewhere in the candidate gene was detected by
direct sequencing.
DISCUSSION
By adding a novel germline large deletion to the repertoire of
germline CDKN2A mutations, our data contribute to an enlarge-
ment of the spectrum of mutations identified in melanoma-
prone families and improve the estimate of the prevalence of this
type of lesion, as the work was performed on the largest family
dataset to date. Among the 214 melanoma-prone families recruited
through the French Familial Melanoma Project, 46 families were
positive for point mutations within CDKN2A (21.5%), one family
carried a CDK4 point mutation in exon 2 (0.5%), and one family
carried a large CDKN2A deletion (0.5%). Overall, a genetic
alteration affecting either CDKN2A or CDK4 was detected in 48
of 214 (22.4%) of the French CMM families. Point mutations
account for 97.9% (47 of 48), and large genomic rearrangements
account for 2.1% (1 of 48) of CDKN2A/CDK4 mutations.
The frequency of such alterations detectable by MLPA in CMM
families negative for point mutations in CDKN2A and CDK4
(0.6%; 1 of 167 pedigrees screened) is even lower than frequencies
reported in the UK population, 3.2% (3 of 93 pedigrees screened)
(Mistry et al, 2005). Therefore, the question of systematic MLPA
screening in pedigrees with no point mutations in the coding
sequence of CDKN2A could be debated, as such screening will not
improve substantially the sensitivity of genetic testing.
Owing to the overlapping open reading frames in exon 2, this
deletion of CDKN2A is a new example of a germline mutation
affecting p16 and p14 proteins, two major regulators of cell cycle
progression and survival through the pRb and p53 pathways,
respectively. The functional relevance of this genomic deletion is
inferred based on three observations: (1) the knowledge that p16
proteins with less than 120 residues lack the capacity to bind to and
inhibit CDK (Parry and Peters, 1996, Hashemi et al, 2000, 2002), (2)
loss of CDKN2A exon 2 has been shown to reduce the activity of p14
(Hashemi et al, 2000, 2002), (3) both p14 and p16 mRNA lacking
exon 2 are translated into truncated proteins when expressed
exogenously (Hashemi et al, 2000). In addition, it is also possible
that the CDKN2A exon 2 deletion leads to aberrant transcripts,
which are the target of the nonsense-mediated mRNA decay
mechanism, thus preventing the synthesis of truncated p14 and p16.
Interestingly, three other gross deletions at the CDKN2A locus,
impacting on both p16 and p14, have been reported from
melanoma-NST families (Bahuau et al, 1998; Randerson-Moor
et al, 2001; Mistry et al, 2005; Pasmant et al, 2007), and a splice site
mutation removing CDKN2A exon 2 was also found in a
melanoma/neurofibroma family (Petronzelli et al, 2001). However,
Exon 1β Exon 1α Exon 2 Exon 3
Del 2935 bp
Exon 1α + 1712 bp Exon 2 + 873 bp
Wild-type p16INK4A mRNA
Wild-type p14ARF mRNA
Truncated p16INK4A mRNA
Truncated p14ARF mRNA
Figure 1 Characterization of the new CDKN2A deletion. (A) Genemap of the CDKN2A locus. Breakpoints of the deletion (exon 1a þ1712bp_exon 2
þ873bp) are indicated and illustrated by the sequence chromatogram. (B) Comparison of the wild type p16
INK4A and p14
ARF transcripts arising from the
allele harbouring the deletion. The truncated transcripts are lacking exon 2. This alters the reading frame of both transcripts.
Melanoma
Pancreatic cancer
Cancer (no data)
Patient carrying the deletion of CDKNA2A exon 2
Figure 2 Family tree of patient carrying the CDKN2A exon 2 deletion.
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sthere was no evidence of NST in the family with the novel CDKN2A
deletion presented here, although clinical description of this family
was very basic.
Methods used to screen for mutations in CDKN2A/ARF are
usually PCR-based and focus on the detection of small sequences
alterations, such as point mutations, small deletions and
insertions. Few investigators have systematically searched for
large CDKN2A/ARF deletions or rearrangements (Fitzgerald et al,
1996; Debniak et al, 2004; Mistry et al, 2005). We chose to apply
MLPA analysis to determine whether large deletions or rearrange-
ments occur at the CDKN2A/ARF locus on 9p21 in French CMM
families; however, the failure to detect large deletions using this
technique does not exclude the possibility that large deletions may
exist, as the probes used do not cover the entire genomic sequence
of CDKN2A. Moreover, neither inversions, nor translocations are
detectable by this approach, and such genomic alterations cannot
be ruled out in melanoma families where no CDKN2A mutation
has been detected. Furthermore, the possibility of alteration
at the transcript level in high-risk families with no mutation
identified through conventional testing should be considered
(Knappskog et al, 2006). As we did not employ RT–PCR, deep
intronic mutations that have the potential to alter intron/exon
splicing could have been missed. Finally, absence of CDKN2A
mutation or large deletion does not rule out the possibility that
epigenetic modification of either p16 or p14ARF could result in gene
silencing that would contribute to melanoma (Merlo et al,1 9 9 5 ;
Esteller et al, 2000). Such a germline epimutation silencing the DNA
mismatch repair gene MLH1 has been reported in nonpolyposis
colorectal cancer (Suter et al, 2004; Hitchins et al, 2007).
In conclusion, although approximately 50% of melanoma-prone
families display linkage to 9p21, only about half of these have been
identified as carriers of mutations in the CDKN2A gene by direct
Chromosome 9
Mb
p tel Cen
21.4 21.5 21.6 21.7 21.3 21.8 21.9 22.0
p24.1 9q12 q21.13 9q31.1 31.3 32 33.233.3 34.3 q33.1 9p23 9p21.3 p21.113.3 12 11.2
KLHL9
FNA6
IFNA13
IFNA2
IFNA1
IFNE1
RefSeq Genes
MTAP CDKN2A
CDKN2A
CDKN2A
CDKN2B
CDKN2B
IFNA8
Figure 3 Overview of the 9p21 region containing KLHL9 and CDKN2A locus.
T
T
A
A
Probe ligation product No probe ligation product
PCR primer
sequence
PCR primer
sequence PCR primer
sequence
PCR primer
sequence
Hybridisation sequence Hybridisation sequence Hybridisation sequence Hybridisation sequence
Target WT Target MUT
START START
Patient DNA Control DNA
–16 bp A>G
G
T
Figure 4 Identification of KLHL9 variant. (A) Principle of MLPA analysis: the patient carrying the variant shows a reduced amount of amplification product
for probes specific of the promoter region of KLHL9. (B) Sequence chromatograms illustrating the nucleotidic change A4G at position –16 of the gene that
prevents the ligation reaction.
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sexon sequencing (Hussussian et al, 1994; Kamb et al, 1994;
Harland et al, 1997; Borg et al, 2000). Few of the melanoma-prone
families tested here were sufficiently informative to assess for
linkage to 9p21. However, the present work provides evidence that
only a small fraction of the unexplained familial risk of CMM is
attributable to large deletions of CDKN2A locus. Therefore, there
may be yet unidentified highly penetrant melanoma susceptibility
genes located at the 9p21 locus. The finding of the 50UTR variant
within KLHL9, located 630kb from CDKN2A on 9p21 in one
melanoma patient was serendipitous. Little is known about the
biological function of KLHL9 itself, but Kelch-superfamily proteins
participate in various cellular activities, and functions of family
members impinge on cell morphology, cell organisation and gene
expression. KLHL (kelch homologue) genes contain two evolu-
tionary conserved domains: a broad-complex, tramtrack, bric-a `-
brac/proxvirus and zinc finger (BTB/POZ) domain, and a kelch
motif, which is a human homologue of the Drosophila kelch gene.
Kelch-like proteins are much conserved, and some family
members have been implicated in embryogenesis and carcinogen-
esis through cytoskeleton organisation (Adams et al, 2000; Liang
et al, 2004; Yoshida, 2005). Thus, as for other BTB/kelch repeat
proteins, we hypothesized that loss of function of KLHL9 may
contribute to tumorigenesis by promoting cell proliferation,
suppressing apoptosis, and/or by affecting nuclear cytoskeleton
dynamics. Although the 50UTR variant within KLHL9 was absent
in a French control population, we ruled out major involvement of
KLHL9 in the susceptibility to melanoma by screening the entire
coding sequence of the candidate gene in a panel of 42 high-risk
CMM families. Recently, a new large antisense non coding RNA,
named ANRIL, has been identified at the CDKN2A locus, with a
first exon located in the promoter of the p14/ARF gene and
overlapping the two exons of p15/CDKN2B (Pasmant et al, 2007).
As ANRIL was localised within the 403kb deletion in the French
melanoma-NST family (Bahuau et al, 1998), it has been
hypothesized that this new gene could be involved melanoma-
NST syndrome families and in melanoma-prone families with no
identified CDKN2A mutations. The possible involvement of ANRIL
has not been investigated yet, and further studies should elucidate
the role of this gene in the susceptibility to CMM.
Finally, efforts are currently underway to identify new high
penetrance susceptibility genes on other chromosomes, as there
remain a significant proportion of CMM families (B50%) that are
not linked to chromosome 9p21. Such genes may lie at 1p36
(Goldstein et al, 1993) and 1p22 (Gillanders et al, 2003).
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